Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Cush

Rheumatology Dallas, TX Medical Doctor

NPI 1265492680 CMS profile 284719

9900 N Central Expy, Suite 550, Dallas, TX 75231

Open in the dashboard

General payments

$3,696,836

632 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$248,028 paid to institutions, not to them · program years 2019–2020

Through program year 2025, John Cush of Dallas, TX is reported in the CMS Open Payments database as having received $3,696,836 across 632 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $248,028 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $606,128 131
2024 General $717,961 110
2023 General $686,541 123
2022 General $732,039 96
2021 General $508,025 30
2020 General $311,379 27
2019 General $134,764 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Cush
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to John Cush were reported at $606,128. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year John Cush Rheumatology median Middle half National median
2019 $134,764 $744 $153–$2,687 $163
2020 $311,379 $462 $98–$2,027 $114
2021 $508,025 $531 $101–$2,153 $132
2022 $732,039 $627 $125–$2,303 $149
2023 $686,541 $741 $145–$2,524 $160
2024 $717,961 $830 $166–$2,660 $164
2025 $606,128 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,350,050 129 payments
  2. Novartis Pharmaceuticals Corporation $788,541 136 payments
  3. E.R. Squibb & Sons, L.L.C. $397,601 61 payments
  4. UCB, Inc. $48,445 42 payments
  5. Pfizer Inc. $34,170 61 payments
  6. Genentech USA, Inc. $29,154 11 payments
  7. Janssen Scientific Affairs, LLC $16,016 117 payments
  8. Amgen Inc. $7,120 6 payments
  9. Gilead Sciences, Inc. $6,636 7 payments
  10. Eli Lilly and Company $5,600 1 payment
  11. Other $13,503 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,448,387 95 payments
  2. Grant $909,500 6 payments
  3. Consulting Fee $263,655 70 payments
  4. Travel and Lodging $39,868 202 payments
  5. Honoraria $28,981 31 payments
  6. Food and Beverage $6,378 226 payments
  7. Education $66 2 payments
Products named General payments · program years 2019–2025
  1. HUMIRA $1,264,959 50 payments
  2. RINVOQ Immunology $852,535 16 payments
  3. COSENTYX $413,179 17 payments
  4. ILARIS $291,333 18 payments
  5. ORENCIA $280,832 12 payments
  6. RINVOQ Immunology $215,679 3 payments
  7. SKYRIZI $50,000 1 payment
  8. Bimzelx $33,284 33 payments
  9. Actemra $29,154 11 payments
  10. TREMFYA $16,016 117 payments
  11. Other $52,057 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

632 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record